357
Views
24
CrossRef citations to date
0
Altmetric
Original Research

The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies

, , &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (7)

Eleonora Tulli, Giuseppe Di Cara, Giulia Iapadre, Pasquale Striano & Alberto Verrotti. (2021) An update on brivaracetam for the treatment of pediatric partial epilepsy. Expert Opinion on Pharmacotherapy 22:11, pages 1387-1395.
Read now
Giangennaro Coppola, Giulia Iapadre, Francesca Felicia Operto & Alberto Verrotti. (2017) New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Design, Development and Therapy 11, pages 643-657.
Read now
Jasmina R. Milovanović, Slobodan M. Janković, Ana Pejčić, Miloš Milosavljević, Valentina Opančina, Vesela Radonjić, Zoran Protrka & Marina Kostić. (2017) Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opinion on Pharmacotherapy 18:13, pages 1381-1389.
Read now
Lan Gao & Shuchuen Li. (2016) Emerging drugs for partial-onset epilepsy: a review of brivaracetam. Therapeutics and Clinical Risk Management 12, pages 719-734.
Read now
Adam Strzelczyk, Karl Martin Klein, Laurent M. Willems, Felix Rosenow & Sebastian Bauer. (2016) Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Review of Clinical Pharmacology 9:5, pages 637-645.
Read now
Edoardo Ferlazzo, Emilio Russo, Laura Mumoli, Chiara Sueri, Sara Gasparini, Caterina Palleria, Angelo Labate, Antonio Gambardella, Giovambattista De Sarro & Umberto Aguglia. (2015) Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatric Disease and Treatment 11, pages 2967-2973.
Read now
Laura Mumoli, Caterina Palleria, Sara Gasparini, Rita Citraro, Angelo Labate, Edoardo Ferlazzo, Antonio Gambardella, Giovambattista De Sarro & Emilio Russo. (2015) Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Design, Development and Therapy 9, pages 5719-5725.
Read now

Articles from other publishers (17)

Rebecca Bresnahan, Mariangela Panebianco & Anthony G Marson. (2022) Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database of Systematic Reviews 2022:3.
Crossref
J. Adewusi, C. Burness, S. Ellawela, H. Emsley, R. Hughes, C. Lawthom, M. Maguire, B. McLean, R. Mohanraj, M. Oto, S. Singhal & M. Reuber. (2020) Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation. Epilepsy & Behavior 106, pages 106967.
Crossref
Rebecca Bresnahan, Mariangela Panebianco & Anthony G Marson. (2019) Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database of Systematic Reviews 2019:8.
Crossref
Martin Hirsch, Mandy Hintz, Anja Specht & Andreas Schulze-Bonhage. (2018) Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis. Seizure 61, pages 98-103.
Crossref
Jeremy Slater, Steve Chung, Lynn Huynh, Mei Sheng Duh, Brian Gorin, Carolyn McMicken, Adam Ziemann & Jouko Isojarvi. (2018) Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. Epilepsy Research 143, pages 120-129.
Crossref
Alexis Arzimanoglou, O’Neill D’Cruz, Douglas Nordli, Shlomo Shinnar & Gregory L. Holmes. (2018) A Review of the New Antiepileptic Drugs for Focal-Onset Seizures in Pediatrics: Role of Extrapolation. Pediatric Drugs 20:3, pages 249-264.
Crossref
Linda J. Stephen & Martin J. Brodie. (2017) Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Therapeutic Advances in Neurological Disorders 11, pages 175628561774208.
Crossref
Li-na Zhu, Deng Chen, Tao Chen, Da Xu, Si-han Chen & Ling Liu. (2017) The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials. Seizure 45, pages 7-16.
Crossref
V. A. Karlov, P. N. Vlasov, I. A. Zhidkova, M. Ya. Kissin, A. V. Lebedeva, L. V. Lipatova, V. R. Mkrtchyan, K. Yu. Mukhin & I. G. Rudakova. (2017) Brivaracetam in the treatment of patients with epilepsy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 117:9, pages 55.
Crossref
Christian Brandt, Theodor W. May & Christian G. Bien. (2016) Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base. Therapeutic Advances in Neurological Disorders 9:6, pages 474-482.
Crossref
A. Strzelczyk, I. Steinig, K. M. Klein, L. M. Willems, S. Knake, F. Rosenow & S. Bauer. (2016) Brivaracetam zur Zusatztherapie bei fokalen EpilepsienBrivaracetam for add-on treatment in focal epilepsy. Der Nervenarzt 87:10, pages 1086-1093.
Crossref
Sheridan M. Hoy. (2016) Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy. CNS Drugs 30:8, pages 761-772.
Crossref
Elinor Ben-MenachemRūta MameniškienėPier Paolo QuaratoPavel KleinJessica GamageJimmy SchiemannMartin E. JohnsonJohn WhitesidesBelinda McDonoughKlaus Eckhardt. (2016) Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology 87:3, pages 314-323.
Crossref
Lin Zhang, Shaoping Li, Hua Li & Xiaoyi Zou. (2016) Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison. Seizure 39, pages 28-33.
Crossref
Simona LattanziClaudia CagnettiNicoletta FoschiLeandro ProvincialiMauro Silvestrini. (2016) Brivaracetam add-on for refractory focal epilepsy. Neurology 86:14, pages 1344-1352.
Crossref
Gaetano Zaccara & Dieter Schmidt. (2016) Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. Pharmacological Research 104, pages 38-48.
Crossref
Brian Spoelhof, Lynn Frendak, Nicole Kiehle, Ashley Martinelli & Lucia Rivera Lara. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 55 70 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.